-
Y.
Janjigian,
J.
Bendell,
E.
Calvo,
Joseph
Kim,
P.
Ascierto,
P.
Sharma,
P.
Ott,
K.
Peltola,
D.
Jaeger,
J.
Evans,
F.
Braud,
I.
Chau,
C.
Harbison,
C.
Dorange,
M.
Tschaika,
D.
Le
(2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Journal of Clinical Oncology, 36
-
Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis
-
(
TorreLABrayFSiegelRL, et al
Global cancer statistics, 2012. CA Cancer J Clin
2015; 65: 87–108.25651787)
TorreLABrayFSiegelRL, et al
Global cancer statistics, 2012. CA Cancer J Clin
2015; 65: 87–108.25651787
TorreLABrayFSiegelRL, et al
Global cancer statistics, 2012. CA Cancer J Clin
2015; 65: 87–108.25651787,
TorreLABrayFSiegelRL, et al
Global cancer statistics, 2012. CA Cancer J Clin
2015; 65: 87–108.25651787
-
(
KangYKBokuNSatohT, et al
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
2017; 390: 2461–2471.28993052)
KangYKBokuNSatohT, et al
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
2017; 390: 2461–2471.28993052
KangYKBokuNSatohT, et al
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
2017; 390: 2461–2471.28993052,
KangYKBokuNSatohT, et al
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
2017; 390: 2461–2471.28993052
-
(
ZhengYZhuXQRenXG.
Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore)
2017; 96: e6884.28614219)
ZhengYZhuXQRenXG.
Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore)
2017; 96: e6884.28614219
ZhengYZhuXQRenXG.
Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore)
2017; 96: e6884.28614219,
ZhengYZhuXQRenXG.
Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore)
2017; 96: e6884.28614219
-
E.
Smyth,
M.
Verheij,
W.
Allum,
D.
Cunningham,
A.
Cervantes,
D.
Arnold
(2022)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 suppl 5
-
Opdivo ® (Nivolumab) intravenous infusion approved in Taiwan for supplemental indication of advanced or recurrent gastric cancer or gastro-esophageal junction cancer
-
(
US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. Approved Drugs, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm (2017, accessed 17 May 2019).)
US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. Approved Drugs, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm (2017, accessed 17 May 2019).
US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. Approved Drugs, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm (2017, accessed 17 May 2019).,
US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. Approved Drugs, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm (2017, accessed 17 May 2019).
-
(
JanjigianYYOttPACalvoE, et al
CheckMate 032 study: efficacy and safety of nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol
2018; 36: 2836–2844.30110194)
JanjigianYYOttPACalvoE, et al
CheckMate 032 study: efficacy and safety of nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol
2018; 36: 2836–2844.30110194
JanjigianYYOttPACalvoE, et al
CheckMate 032 study: efficacy and safety of nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol
2018; 36: 2836–2844.30110194,
JanjigianYYOttPACalvoE, et al
CheckMate 032 study: efficacy and safety of nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol
2018; 36: 2836–2844.30110194
-
J.
Taieb,
M.
Moehler,
N.
Boku,
J.
Ajani,
E.
Ruiz,
M.
Ryu,
S.
Guenther,
V.
Chand,
Y.
Bang
(2018)
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Cancer treatment reviews, 66
-
(
WilkeHMuroKVan CutsemE, et al
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol
2014; 15: 1224–1235.25240821)
WilkeHMuroKVan CutsemE, et al
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol
2014; 15: 1224–1235.25240821
WilkeHMuroKVan CutsemE, et al
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol
2014; 15: 1224–1235.25240821,
WilkeHMuroKVan CutsemE, et al
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol
2014; 15: 1224–1235.25240821
-
(
KojimaTMuroKFrancoisE, et al
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. J Clin Oncol
2019; 37(Suppl. 4): 2–2. doi:10.1200/JCO.2019.37.4_suppl.2)
KojimaTMuroKFrancoisE, et al
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. J Clin Oncol
2019; 37(Suppl. 4): 2–2. doi:10.1200/JCO.2019.37.4_suppl.2
KojimaTMuroKFrancoisE, et al
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. J Clin Oncol
2019; 37(Suppl. 4): 2–2. doi:10.1200/JCO.2019.37.4_suppl.2,
KojimaTMuroKFrancoisE, et al
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. J Clin Oncol
2019; 37(Suppl. 4): 2–2. doi:10.1200/JCO.2019.37.4_suppl.2
-
(
SmythECVerheijMAllumW, et al
ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol
2016; 27(Suppl. 5): v38–v49.27664260)
SmythECVerheijMAllumW, et al
ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol
2016; 27(Suppl. 5): v38–v49.27664260
SmythECVerheijMAllumW, et al
ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol
2016; 27(Suppl. 5): v38–v49.27664260,
SmythECVerheijMAllumW, et al
ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol
2016; 27(Suppl. 5): v38–v49.27664260
-
(
ShitaraKDoiTDvorkinM, et al
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2018; 19: 1437–1448.30355453)
ShitaraKDoiTDvorkinM, et al
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2018; 19: 1437–1448.30355453
ShitaraKDoiTDvorkinM, et al
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2018; 19: 1437–1448.30355453,
ShitaraKDoiTDvorkinM, et al
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2018; 19: 1437–1448.30355453
-
T.
Kojima,
K.
Muro,
E.
François,
Chih-Hung
Hsu,
T.
Moriwaki,
Sung-Bae
Kim,
Se-Hoon
Lee,
J.
Bennouna,
Ken
Kato,
Shen
Lin,
S.
Qin,
P.
Ferreira,
T.
Doi,
A.
Adenis,
P.
Enzinger,
Manish
Shah,
Rui-xue
Wang,
P.
Bhagia,
S.
Kang,
J.
Metges
(2019)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
Journal of Clinical Oncology
-
S.
Rosa,
N.
Sahnane,
M.
Tibiletti,
F.
Magnoli,
A.
Vanoli,
F.
Sessa,
A.
Chiaravalli
(2018)
EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes
Cancers, 10
-
(2016)
LSKB to report non - clinical rivoceranib ( apatinib ) combination with immunotherapy
-
(
CharalampakisNEconomopoulouPKotsantisI, et al
Medical management of gastric cancer: a 2017 update. Cancer Med
2018; 7: 123–133.29239137)
CharalampakisNEconomopoulouPKotsantisI, et al
Medical management of gastric cancer: a 2017 update. Cancer Med
2018; 7: 123–133.29239137
CharalampakisNEconomopoulouPKotsantisI, et al
Medical management of gastric cancer: a 2017 update. Cancer Med
2018; 7: 123–133.29239137,
CharalampakisNEconomopoulouPKotsantisI, et al
Medical management of gastric cancer: a 2017 update. Cancer Med
2018; 7: 123–133.29239137
-
A.
Jemal,
F.
Bray,
Melissa
Center,
J.
Ferlay,
Elizabeth
Ward,
D.
Forman
(2011)
Global cancer statistics
CA: A Cancer Journal for Clinicians, 61
-
(
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved for supplemental indication of advanced or recurrent gastric or gastroesophageal junction adenocarcinoma and for expanded use in recurrent or advanced classical Hodgkin lymphoma in South Korea, https://www.ono.co.jp/eng/news/pdf/sm_cn180326.pdf (2018, accessed 17 May 2019).)
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved for supplemental indication of advanced or recurrent gastric or gastroesophageal junction adenocarcinoma and for expanded use in recurrent or advanced classical Hodgkin lymphoma in South Korea, https://www.ono.co.jp/eng/news/pdf/sm_cn180326.pdf (2018, accessed 17 May 2019).
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved for supplemental indication of advanced or recurrent gastric or gastroesophageal junction adenocarcinoma and for expanded use in recurrent or advanced classical Hodgkin lymphoma in South Korea, https://www.ono.co.jp/eng/news/pdf/sm_cn180326.pdf (2018, accessed 17 May 2019).,
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved for supplemental indication of advanced or recurrent gastric or gastroesophageal junction adenocarcinoma and for expanded use in recurrent or advanced classical Hodgkin lymphoma in South Korea, https://www.ono.co.jp/eng/news/pdf/sm_cn180326.pdf (2018, accessed 17 May 2019).
-
(
LinSJGagnon-BartschJATanIB, et al
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut
2015; 64: 1721–1731.25385008)
LinSJGagnon-BartschJATanIB, et al
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut
2015; 64: 1721–1731.25385008
LinSJGagnon-BartschJATanIB, et al
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut
2015; 64: 1721–1731.25385008,
LinSJGagnon-BartschJATanIB, et al
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut
2015; 64: 1721–1731.25385008
-
(
Thuss-PatiencePCKretzschmarABichevD, et al
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer
2011; 47: 2306–2314.21742485)
Thuss-PatiencePCKretzschmarABichevD, et al
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer
2011; 47: 2306–2314.21742485
Thuss-PatiencePCKretzschmarABichevD, et al
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer
2011; 47: 2306–2314.21742485,
Thuss-PatiencePCKretzschmarABichevD, et al
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer
2011; 47: 2306–2314.21742485
-
Zin
Myint,
G.
Goel
(2017)
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Journal of Hematology & Oncology, 10
-
T.
Satoh,
L.-T.
Chen,
Y.
Kang,
Y.
Chao,
K.
Kato,
H.
Chung,
J-S.
Chen,
K.
Muro,
W.
Kang,
T.
Yoshikawa,
S.
Oh,
T.
Tamura,
K.
Lee,
N.
Boku
(2018)
A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
E.
Goode,
E.
Smyth
(2016)
Immunotherapy for Gastroesophageal Cancer
Journal of Clinical Medicine, 5
-
(
US Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lonsurf-recurrent-metastatic-gastric-and-gastroesophageal-junction-adenocarcinoma (2019, accessed 17 May 2019).)
US Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lonsurf-recurrent-metastatic-gastric-and-gastroesophageal-junction-adenocarcinoma (2019, accessed 17 May 2019).
US Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lonsurf-recurrent-metastatic-gastric-and-gastroesophageal-junction-adenocarcinoma (2019, accessed 17 May 2019).,
US Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lonsurf-recurrent-metastatic-gastric-and-gastroesophageal-junction-adenocarcinoma (2019, accessed 17 May 2019).
-
(
BokuNKangYKSatohT, et al
A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol
2017; 28(Suppl. 5): mdx369.001. doi:10.1093/annonc/mdx369.001)
BokuNKangYKSatohT, et al
A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol
2017; 28(Suppl. 5): mdx369.001. doi:10.1093/annonc/mdx369.001
BokuNKangYKSatohT, et al
A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol
2017; 28(Suppl. 5): mdx369.001. doi:10.1093/annonc/mdx369.001,
BokuNKangYKSatohT, et al
A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol
2017; 28(Suppl. 5): mdx369.001. doi:10.1093/annonc/mdx369.001
-
(
KangJHLeeSILimDH, et al
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol
2012; 30: 1513–1518.22412140)
KangJHLeeSILimDH, et al
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol
2012; 30: 1513–1518.22412140
KangJHLeeSILimDH, et al
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol
2012; 30: 1513–1518.22412140,
KangJHLeeSILimDH, et al
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol
2012; 30: 1513–1518.22412140
-
(
ChauINormanARCunninghamD, et al
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol
2004; 22: 2395–2403.15197201)
ChauINormanARCunninghamD, et al
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol
2004; 22: 2395–2403.15197201
ChauINormanARCunninghamD, et al
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol
2004; 22: 2395–2403.15197201,
ChauINormanARCunninghamD, et al
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol
2004; 22: 2395–2403.15197201
-
(
ShitaraKÖzgüroğluMBangYJ, et al
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet
2018; 392: 123–133.29880231)
ShitaraKÖzgüroğluMBangYJ, et al
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet
2018; 392: 123–133.29880231
ShitaraKÖzgüroğluMBangYJ, et al
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet
2018; 392: 123–133.29880231,
ShitaraKÖzgüroğluMBangYJ, et al
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet
2018; 392: 123–133.29880231
-
US Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction
-
ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up
-
(
LSK BioPharma. LSKB to report non-clinical rivoceranib (apatinib) combination with immunotherapy, http://lskbiopharma.com/lskb-to-report-non-clinical-rivoceranib-apatinib-combination-with-immunotherapy/ (2018, accessed 17 May 2019).)
LSK BioPharma. LSKB to report non-clinical rivoceranib (apatinib) combination with immunotherapy, http://lskbiopharma.com/lskb-to-report-non-clinical-rivoceranib-apatinib-combination-with-immunotherapy/ (2018, accessed 17 May 2019).
LSK BioPharma. LSKB to report non-clinical rivoceranib (apatinib) combination with immunotherapy, http://lskbiopharma.com/lskb-to-report-non-clinical-rivoceranib-apatinib-combination-with-immunotherapy/ (2018, accessed 17 May 2019).,
LSK BioPharma. LSKB to report non-clinical rivoceranib (apatinib) combination with immunotherapy, http://lskbiopharma.com/lskb-to-report-non-clinical-rivoceranib-apatinib-combination-with-immunotherapy/ (2018, accessed 17 May 2019).
-
(
DavidsonMCafferkeyCGoodeEF, et al
Survival in advanced oesophagogastric adenocarcinoma improves with the use of multiple lines of therapy: results from an analysis of more than 500 patients. Clin Colorectal Cancer
2018; 17: 223–230.29980492)
DavidsonMCafferkeyCGoodeEF, et al
Survival in advanced oesophagogastric adenocarcinoma improves with the use of multiple lines of therapy: results from an analysis of more than 500 patients. Clin Colorectal Cancer
2018; 17: 223–230.29980492
DavidsonMCafferkeyCGoodeEF, et al
Survival in advanced oesophagogastric adenocarcinoma improves with the use of multiple lines of therapy: results from an analysis of more than 500 patients. Clin Colorectal Cancer
2018; 17: 223–230.29980492,
DavidsonMCafferkeyCGoodeEF, et al
Survival in advanced oesophagogastric adenocarcinoma improves with the use of multiple lines of therapy: results from an analysis of more than 500 patients. Clin Colorectal Cancer
2018; 17: 223–230.29980492
-
(
OhtsuAAjaniJABaiYX, et al
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol
2013; 31: 3935–3943.24043745)
OhtsuAAjaniJABaiYX, et al
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol
2013; 31: 3935–3943.24043745
OhtsuAAjaniJABaiYX, et al
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol
2013; 31: 3935–3943.24043745,
OhtsuAAjaniJABaiYX, et al
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol
2013; 31: 3935–3943.24043745
-
(
WolchokJDChiarion-SileniVGonzalezR, et al
Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med
2017; 377: 1345–1356.28889792)
WolchokJDChiarion-SileniVGonzalezR, et al
Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med
2017; 377: 1345–1356.28889792
WolchokJDChiarion-SileniVGonzalezR, et al
Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med
2017; 377: 1345–1356.28889792,
WolchokJDChiarion-SileniVGonzalezR, et al
Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med
2017; 377: 1345–1356.28889792
-
(
De RosaSSahnaneNTibilettiMG, et al
EBV⁺ and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8⁺ intratumoral lymphocytes. Cancers (Basel)
2018; 10; pii: E102.)
De RosaSSahnaneNTibilettiMG, et al
EBV⁺ and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8⁺ intratumoral lymphocytes. Cancers (Basel)
2018; 10; pii: E102.
De RosaSSahnaneNTibilettiMG, et al
EBV⁺ and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8⁺ intratumoral lymphocytes. Cancers (Basel)
2018; 10; pii: E102.,
De RosaSSahnaneNTibilettiMG, et al
EBV⁺ and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8⁺ intratumoral lymphocytes. Cancers (Basel)
2018; 10; pii: E102.
-
M.
Davidson,
C.
Cafferkey,
E.
Goode,
K.
Kouvelakis,
D.
Hughes,
P.
Reguera,
E.
Kalaitzaki,
C.
Peckitt,
S.
Rao,
D.
Watkins,
I.
Chau,
D.
Cunningham,
N.
Starling
(2018)
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients
Clinical Colorectal Cancer, 17
-
FDA grants accelerated approval to pembrolizumab for advanced gastric cancer
-
(
FontanaESmythEC.
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol
2016; 8: 113–125.26929787)
FontanaESmythEC.
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol
2016; 8: 113–125.26929787
FontanaESmythEC.
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol
2016; 8: 113–125.26929787,
FontanaESmythEC.
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol
2016; 8: 113–125.26929787
-
J.
Kang,
S.
Lee,
D.
Lim,
K.
Park,
S.
Oh,
H.
Kwon,
I.
Hwang,
Sang-Cheol
Lee,
E.
Nam,
D.
Shin,
Jeeyun
Lee,
Joon-Oh
Park,
Y.
Park,
Ho
Lim,
W.
Kang,
S.
Park
(2012)
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 13
-
I.
Chau,
S.
Ashley,
D.
Cunningham
(2009)
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 19
-
(
JanowitzTThuss-PatiencePMarshallA, et al
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer
2016; 14: 381–387.)
JanowitzTThuss-PatiencePMarshallA, et al
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer
2016; 14: 381–387.
JanowitzTThuss-PatiencePMarshallA, et al
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer
2016; 14: 381–387.,
JanowitzTThuss-PatiencePMarshallA, et al
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer
2016; 14: 381–387.
-
(
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved in Taiwan for supplemental indication of advanced or recurrent gastric cancer or gastro-esophageal junction cancer, https://www.ono.co.jp/eng/news/pdf/sm_cn180123.pdf (2018, accessed 17 May 2019).)
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved in Taiwan for supplemental indication of advanced or recurrent gastric cancer or gastro-esophageal junction cancer, https://www.ono.co.jp/eng/news/pdf/sm_cn180123.pdf (2018, accessed 17 May 2019).
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved in Taiwan for supplemental indication of advanced or recurrent gastric cancer or gastro-esophageal junction cancer, https://www.ono.co.jp/eng/news/pdf/sm_cn180123.pdf (2018, accessed 17 May 2019).,
Ono Pharmaceutical Co Ltd. Opdivo® (Nivolumab) intravenous infusion approved in Taiwan for supplemental indication of advanced or recurrent gastric cancer or gastro-esophageal junction cancer, https://www.ono.co.jp/eng/news/pdf/sm_cn180123.pdf (2018, accessed 17 May 2019).
-
C.
Fuchs,
T.
Doi,
R.
Jang,
K.
Muro,
T.
Satoh,
M.
Machado,
Weijing
Sun,
S.
Jalal,
M.
Shah,
J.
Metges,
M.
Garrido,
T.
Golan,
M.
Mandalà,
Z.
Wainberg,
D.
Catenacci,
A.
Ohtsu,
K.
Shitara,
R.
Geva,
J.
Bleeker,
A.
Ko,
G.
Ku,
P.
Philip,
P.
Enzinger,
Y.
Bang,
D.
Levitan,
Jiangdian
Wang,
M.
Rosales,
R.
Dalal,
H.
Yoon
(2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
JAMA Oncology, 4
-
K.
Shitara,
T.
Doi,
M.
Dvorkin,
W.
Mansoor,
H.
Arkenau,
A.
Prokharau,
M.
Alsina,
M.
Ghidini,
C.
Faustino,
V.
Gorbunova,
E.
Zhavrid,
K.
Nishikawa,
A.
Hosokawa,
Ş.
Yalçın,
K.
Fujitani,
G.
Beretta,
E.
Cutsem,
R.
Winkler,
L.
Makris,
D.
Ilson,
J.
Tabernero
(2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 19 11
-
Lindsey
Torre,
F.
Bray,
R.
Siegel,
J.
Ferlay,
J.
Lortet-Tieulent,
A.
Jemal
(2015)
Global cancer statistics, 2012
CA: A Cancer Journal for Clinicians, 65
-
S.
Lin,
Johann
Gagnon-Bartsch,
I.
Tan,
S.
Earle,
Louise
Ruff,
K.
Pettinger,
B.
Ylstra,
N.
Grieken,
S.
Rha,
H.
Chung,
Ju-Seog
Lee,
J.
Cheong,
S.
Noh,
T.
Aoyama,
Y.
Miyagi,
A.
Tsuburaya,
T.
Yoshikawa,
J.
Ajani,
A.
Boussioutas,
K.
Yeoh,
W.
Yong,
J.
So,
Jeeyun
Lee,
W.
Kang,
Sung
Kim,
Y.
Kameda,
T.
Arai,
A.
Hausen,
T.
Speed,
H.
Grabsch,
P.
Tan
(2014)
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Gut, 64
-
FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma
-
(
ZhaoBZhangWYuD, et al
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med
2018; 7: 1642–1659.29573217)
ZhaoBZhangWYuD, et al
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med
2018; 7: 1642–1659.29573217
ZhaoBZhangWYuD, et al
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med
2018; 7: 1642–1659.29573217,
ZhaoBZhangWYuD, et al
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med
2018; 7: 1642–1659.29573217
-
(
GoodeEFSmythEC.
Immunotherapy for gastroesophageal cancer. J Clin Med
2016; 5: 84.)
GoodeEFSmythEC.
Immunotherapy for gastroesophageal cancer. J Clin Med
2016; 5: 84.
GoodeEFSmythEC.
Immunotherapy for gastroesophageal cancer. J Clin Med
2016; 5: 84.,
GoodeEFSmythEC.
Immunotherapy for gastroesophageal cancer. J Clin Med
2016; 5: 84.
-
(
BangYJRuizEYVan CutsemE, et al
Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol
2018; 29: 2052–2060.30052729)
BangYJRuizEYVan CutsemE, et al
Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol
2018; 29: 2052–2060.30052729
BangYJRuizEYVan CutsemE, et al
Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol
2018; 29: 2052–2060.30052729,
BangYJRuizEYVan CutsemE, et al
Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol
2018; 29: 2052–2060.30052729
-
Y.
Bang,
E.
Ruiz,
E.
Cutsem,
K.
Lee,
L.
Wyrwicz,
M.
Schenker,
M.
Alsina,
M.
Ryu,
H.
Chung,
L.
Evesque,
Salah-Eddin
Al-Batran,
Silvia
Park,
M.
Lichinitser,
N.
Boku,
M.
Moehler,
Janet
Hong,
H.
Xiong,
R.
Hallwachs,
Ilaria
Conti,
J.
Taieb
(2018)
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Annals of Oncology, 29
-
P.
Thuss-Patience,
A.
Kretzschmar,
D.
Bichev,
T.
Deist,
A.
Hinke,
K.
Breithaupt,
Y.
Doğan,
B.
Gebauer,
G.
Schumacher,
P.
Reichardt
(2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
European journal of cancer, 47 15
-
I.
Chau,
A.
Norman,
D.
Cunningham,
J.
Waters,
J.
Oates,
P.
Ross
(2004)
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 12
-
CheckMate 032 study: efficacy and safety of nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer
-
(
FanottoVUccelloMPecoraI, et al
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist
2018; 22: 1463–1469.)
FanottoVUccelloMPecoraI, et al
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist
2018; 22: 1463–1469.
FanottoVUccelloMPecoraI, et al
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist
2018; 22: 1463–1469.,
FanottoVUccelloMPecoraI, et al
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist
2018; 22: 1463–1469.
-
A.
Ohtsu,
J.
Ajani,
Y.
Bai,
Y.
Bang,
H.
Chung,
H.
Pan,
T.
Sahmoud,
L.
Shen,
K.
Yeh,
K.
Chin,
K.
Muro,
Yeul-Hong
Kim,
D.
Ferry,
N.
Tebbutt,
S.
Al-Batran,
Heind
Smith,
C.
Costantini,
S.
Rizvi,
D.
Lebwohl,
E.
Cutsem
(2013)
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 31
-
K.
Shitara,
M.
Özgüroğlu,
Y.
Bang,
M.
Bartolomeo,
M.
Mandalà,
M.
Ryu,
L.
Fornaro,
T.
Olesiński,
C.
Caglevic,
H.
Chung,
K.
Muro,
E.
Goekkurt,
W.
Mansoor,
R.
McDermott,
E.
Shacham-Shmueli,
Xinqun
Chen,
C.
Mayo,
S.
Kang,
A.
Ohtsu,
C.
Fuchs,
G.
Lerzo,
J.
O'Connor,
G.
Mendez,
J.
Lynam,
N.
Tebbutt,
M.
Wong,
A.
Strickland,
C.
Karapetis,
D.
Goldstein,
P.
Vasey,
J.
Laethem,
E.
Cutsem,
S.
Berry,
M.
Vincent,
Bettina
Muller,
F.
Rey,
A.
Zambrano,
J.
Guerra,
M.
Krogh,
L.
Baeksgaard,
M.
Yilmaz,
A.
Elme,
Andrus
Magi,
P.
Auvinen,
T.
Alanko,
M.
Moehler,
V.
Kunzmann,
T.
Seufferlein,
P.
Thuss-Patience,
T.
Hoehler,
G.
Haag,
S.
Al-Batran,
H.
Castro,
Karla
Lopez,
Mynor
Vasquez,
Mario
Sandoval,
K.
Lam,
S.
Cuffe,
C.
Kelly,
R.
Geva,
A.
Hubert,
A.
Beny,
B.
Brenner,
Aprile
Giuseppe,
A.
Falcone,
E.
Maiello,
R.
Passalacqua,
V.
Montesarchio,
H.
Hara,
K.
Chin,
T.
Nishina,
Y.
Komatsu,
N.
Machida,
S.
Hironaka,
T.
Satoh,
T.
Tamura,
Naotaoshi
Sugimoto,
Haruhiko
Cho,
Yashushi
Omuro,
Ken
Kato,
M.
Goto,
I.
Hyodo,
Kazuhiro
Yoshida,
H.
Baba,
T.
Esaki,
J.
Furuse,
Wan
Mohammed,
Carlos
Hernandez,
Juan
Garcia,
Adriana
Andrade,
Katriona
Clarke,
G.
Hjortland,
N.
Glenjen,
T.
Kubiatowski,
J.
Jacek,
M.
Wojtukiewicz,
S.
Lazarev,
Yuri
Lancukhay,
Sergey
Afanasayev,
V.
Moiseyenko,
V.
Kostorov,
S.
Protsenko,
V.
Shirinkin,
D.
Sakaeva,
N.
Fadeeva,
W.
Yong,
C.
Ng,
B.
Robertson,
B.
Rapaport,
G.
Cohen,
L.
Dreosti,
P.
Ruff,
C.
Jacobs,
G.
Landers,
W.
Szpak,
S.
Roh,
Jeeyun
Lee,
Yeul-Hong
Kim,
H.
Chung,
María
Maqueda,
F.
Muñoz,
Andres
Aguilar,
E.
Aguilar,
P.
Alfonso,
F.
Rivera,
Jaime
Batle,
R.
Cid,
K.
Yeh,
Jen‐Shi
Chen,
Y.
Chao,
C.
Yen,
O.
Kara,
Ş.
Yalçın,
D.
Hochhauser,
I.
Chau,
A.
Benson,
V.
Shankaran,
W.
Shaib,
P.
Philip,
V.
Sharma,
R.
Siegel,
Weijing
Sun,
Z.
Wainberg,
B.
George,
A.
Bullock,
S.
Myrick,
Josephine
Faruol,
Richard
Siegel,
T.
Larson,
C.
Becerra,
Suresh
Ratnam,
D.
Richards,
Stephen
Riche
(2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
The Lancet, 392
-
V.
Fanotto,
M.
Uccello,
I.
Pecora,
L.
Rimassa,
F.
Leone,
G.
Rosati,
D.
Santini,
R.
Giampieri,
S.
Donato,
G.
Tomasello,
N.
Silvestris,
F.
Pietrantonio,
F.
Battaglin,
A.
Avallone,
M.
Scartozzi,
E.
Lutrino,
D.
Melisi,
L.
Antonuzzo,
A.
Pellegrino,
L.
Ferrari,
R.
Bordonaro,
C.
Vivaldi,
L.
Gerratana,
S.
Bozzarelli,
R.
Filippi,
D.
Bilancia,
M.
Russano,
G.
Aprile
(2017)
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.
The oncologist, 22 12
-
(
SatohTChenLTKangYK, et al
A phase 3 study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): two-years update data. Ann Oncol
2018; 29(Suppl. 8): mdy282.002. doi:10.1093/annonc/mdy282.002)
SatohTChenLTKangYK, et al
A phase 3 study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): two-years update data. Ann Oncol
2018; 29(Suppl. 8): mdy282.002. doi:10.1093/annonc/mdy282.002
SatohTChenLTKangYK, et al
A phase 3 study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): two-years update data. Ann Oncol
2018; 29(Suppl. 8): mdy282.002. doi:10.1093/annonc/mdy282.002,
SatohTChenLTKangYK, et al
A phase 3 study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): two-years update data. Ann Oncol
2018; 29(Suppl. 8): mdy282.002. doi:10.1093/annonc/mdy282.002
-
N.
Boku,
Y.
Kang,
T.
Satoh,
Y.
Chao,
K.
Kato,
H.
Chung,
J-S.
Chen,
K.
Muro,
W.
Kang,
T.
Yoshikawa,
S.
Oh,
T.
Tamura,
K.
Lee,
L.
Chen
(2017)
617OA Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
Annals of Oncology, 28
-
(
ChanWLYuenKKSiuSW, et al
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol
2017; 116: 68–81.28693801)
ChanWLYuenKKSiuSW, et al
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol
2017; 116: 68–81.28693801
ChanWLYuenKKSiuSW, et al
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol
2017; 116: 68–81.28693801,
ChanWLYuenKKSiuSW, et al
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol
2017; 116: 68–81.28693801
-
J.
Wolchok,
V.
Chiarion-Sileni,
R.
Gonzalez,
P.
Rutkowski,
J.
Grob,
L.
Cowey,
C.
Lao,
J.
Wagstaff,
D.
Schadendorf,
P.
Ferrucci,
M.
Smylie,
R.
Dummer,
A.
Hill,
D.
Hogg,
J.
Haanen,
M.
Carlino,
O.
Bechter,
M.
Maio,
I.
Márquez-Rodas,
M.
Guidoboni,
G.
McArthur,
C.
Lebbé,
P.
Ascierto,
G.
Long,
J.
Cebon,
J.
Sosman,
M.
Postow,
M.
Callahan,
D.
Walker,
L.
Rollin,
R.
Bhore,
S.
Hodi,
J.
Larkin
(2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
The New England Journal of Medicine, 377
-
Yoon-Koo
Kang,
N.
Boku,
T.
Satoh,
M.
Ryu,
Y.
Chao,
Ken
Kato,
H.
Chung,
Jen‐Shi
Chen,
K.
Muro,
W.
Kang,
K.
Yeh,
T.
Yoshikawa,
S.
Oh,
L.
Bai,
T.
Tamura,
Keun-Wook
Lee,
Y.
Hamamoto,
Jong
Kim,
K.
Chin,
D.
Oh,
K.
Minashi,
J.
Cho,
M.
Tsuda,
Li‐Tzong
Chen
(2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, 390
-
(
TaiebJMoehlerMBokuN, et al
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev
2018; 66: 104–113.29730461)
TaiebJMoehlerMBokuN, et al
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev
2018; 66: 104–113.29730461
TaiebJMoehlerMBokuN, et al
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev
2018; 66: 104–113.29730461,
TaiebJMoehlerMBokuN, et al
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev
2018; 66: 104–113.29730461
-
N.
Charalampakis,
P.
Economopoulou,
I.
Kotsantis,
M.
Tolia,
Dimitrios
Schizas,
T.
Liakakos,
E.
Elimova,
J.
Ajani,
A.
Psyrri
(2017)
Medical management of gastric cancer: a 2017 update
Cancer Medicine, 7
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
W.
Chan,
K.
Yuen,
S.
Siu,
K.
Lam,
D.
Kwong
(2017)
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis.
Critical reviews in oncology/hematology, 116
-
Yu
Zheng,
Xuqing
Zhu,
X.
Ren
(2017)
Third-line chemotherapy in advanced gastric cancer
Medicine, 96
-
N.
Pavlakis,
K.
Sjoquist,
A.
Martin,
Eric
Tsobanis,
S.
Yip,
Yoon-Koo
Kang,
Y.
Bang,
T.
Alcindor,
C.
O'Callaghan,
M.
Burnell,
N.
Tebbutt,
S.
Rha,
Jeeyun
Lee,
J.
Cho,
L.
Lipton,
M.
Wong,
A.
Strickland,
J.
Kim,
J.
Zalcberg,
J.
Simes,
D.
Goldstein
(2016)
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 23
-
T.
Janowitz,
P.
Thuss-Patience,
A.
Marshall,
J.
Kang,
Claire
Connell,
N.
Cook,
J.
Dunn,
S.
Park,
H.
Ford
(2016)
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
British Journal of Cancer, 114
-
Jin
Li,
S.
Qin,
Jianming
Xu,
J.
Xiong,
Changping
Wu,
Y.
Bai,
Wei
Liu,
J.
Tong,
Yunpeng
Liu,
R.
Xu,
Zhehai
Wang,
Qiong
Wang,
X.
Ouyang,
Yan
Yang,
Y.
Ba,
Jun
Liang,
Xiaoyan
Lin,
D.
Luo,
R.
Zheng,
Xin
Wang,
G.
Sun,
Li-wei
Wang,
Leizhen
Zheng,
Hong
Guo,
Jingbo
Wu,
N.
Xu,
Jianwei
Yang,
Hong-gang
Zhang,
Ying
Cheng,
Ningju
Wang,
Lei
Chen,
Zhi-lu
Fan,
Piaoyang
Sun,
Hao
Yu
(2016)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 13
-
(
FuchsCSDoiTJangRW, et al
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol
2018; 4: e180013.29543932)
FuchsCSDoiTJangRW, et al
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol
2018; 4: e180013.29543932
FuchsCSDoiTJangRW, et al
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol
2018; 4: e180013.29543932,
FuchsCSDoiTJangRW, et al
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol
2018; 4: e180013.29543932
-
(
EdwardsPDavidsonMCalamaiV, et al
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. Cancer Treat Rev
2018; 71: 32–38.30343173)
EdwardsPDavidsonMCalamaiV, et al
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. Cancer Treat Rev
2018; 71: 32–38.30343173
EdwardsPDavidsonMCalamaiV, et al
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. Cancer Treat Rev
2018; 71: 32–38.30343173,
EdwardsPDavidsonMCalamaiV, et al
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. Cancer Treat Rev
2018; 71: 32–38.30343173
-
Binghao
Zhao,
Wenxiong
Zhang,
Dong-liang
Yu,
Jianjun
Xu,
Yiping
Wei
(2018)
The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials
Cancer Medicine, 7
-
(
ChauIAshleySCunninghamD.
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol
2009; 27: e3–e4.19470917)
ChauIAshleySCunninghamD.
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol
2009; 27: e3–e4.19470917
ChauIAshleySCunninghamD.
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol
2009; 27: e3–e4.19470917,
ChauIAshleySCunninghamD.
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol
2009; 27: e3–e4.19470917
-
E.
Fontana,
E.
Smyth
(2016)
Novel targets in the treatment of advanced gastric cancer: a perspective review
Therapeutic Advances in Medical Oncology, 8
-
L.
Hess,
D.
Michael,
D.
Mytelka,
J.
Beyrer,
A.
Liepa,
S.
Nicol
(2015)
Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data
Gastric Cancer, 19
-
(
MyintZWGoelG.
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol
2017; 10: 86.28434400)
MyintZWGoelG.
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol
2017; 10: 86.28434400
MyintZWGoelG.
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol
2017; 10: 86.28434400,
MyintZWGoelG.
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol
2017; 10: 86.28434400
-
Jin
Li,
S.
Qin,
Jianming
Xu,
Weijian
Guo,
J.
Xiong,
Y.
Bai,
G.
Sun,
Yan
Yang,
Li-wei
Wang,
N.
Xu,
Ying
Cheng,
Zhehai
Wang,
Leizhen
Zheng,
M.
Tao,
Xiaodong
Zhu,
D.
Ji,
Xin
Liu,
Hao
Yu
(2013)
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 26
-
Opdivo® (Nivolumab) intravenous infusion approved for supplemental indication of advanced or recurrent gastric or gastroesophageal junction adenocarcinoma and for expanded use in recurrent or advanced classical Hodgkin lymphoma in South Korea
-
(
LiJQinSXuJ, et al
Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol
2016; 34: 1448–1454.26884585)
LiJQinSXuJ, et al
Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol
2016; 34: 1448–1454.26884585
LiJQinSXuJ, et al
Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol
2016; 34: 1448–1454.26884585,
LiJQinSXuJ, et al
Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol
2016; 34: 1448–1454.26884585
-
H.
Wilke,
K.
Muro,
E.
Cutsem,
S.
Oh,
G.
Bodoky,
Y.
Shimada,
S.
Hironaka,
N.
Sugimoto,
O.
Lipatov,
Tae-You
Kim,
D.
Cunningham,
P.
Rougier,
Y.
Komatsu,
J.
Ajani,
M.
Emig,
R.
Carlesi,
D.
Ferry,
K.
Chandrawansa,
J.
Schwartz,
A.
Ohtsu
(2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
The Lancet. Oncology, 15 11
-
(
HessLMMichaelDMytelkaDS, et al
Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer
2016; 19: 607–615.25792290)
HessLMMichaelDMytelkaDS, et al
Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer
2016; 19: 607–615.25792290
HessLMMichaelDMytelkaDS, et al
Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer
2016; 19: 607–615.25792290,
HessLMMichaelDMytelkaDS, et al
Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer
2016; 19: 607–615.25792290
-
(
PavlakisNSjoquistKMMartinAJ, et al
Regorafenib for the treatment of advanced gastric Cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol
2016; 34: 2728–2735.27325864)
PavlakisNSjoquistKMMartinAJ, et al
Regorafenib for the treatment of advanced gastric Cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol
2016; 34: 2728–2735.27325864
PavlakisNSjoquistKMMartinAJ, et al
Regorafenib for the treatment of advanced gastric Cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol
2016; 34: 2728–2735.27325864,
PavlakisNSjoquistKMMartinAJ, et al
Regorafenib for the treatment of advanced gastric Cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol
2016; 34: 2728–2735.27325864
-
P.
Edwards,
Michael
Davidson,
V.
Calamai,
David
Cunningham,
N.
Starling
(2018)
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends.
Cancer treatment reviews, 71